Membranous Nephropathy: Current Understanding in The Light of New Advances

Basit Öğe Kaydı
dc.authoridOZER, Hakan/0000-0001-9174-0351
dc.contributor.authorOzer, Hakan
dc.contributor.authorBaloglu, Ismail
dc.contributor.authorFervenza, Fernando C.
dc.contributor.authorTurkmen, Kultigin
dc.date.accessioned2024-11-07T13:32:57Z
dc.date.available2024-11-07T13:32:57Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractMembranous nephropathy is the most common cause of primary nephrotic syndrome in adults. The most important mech-anism in its pathogenesis is loss of immune tolerance. New developments in membranous nephropathy are mostly related to the diagnosis and treatment of the disease, and until recently, the gold standard method in diagnosis was a kidney biopsy. In recent years, many membranous nephropathy-associated antigens and antibodies have been identified. The increased availability of these biomarkers is beneficial in predicting the treatment response, determining the treatment plan, and eliminating the necessity of kidney biopsy in the diagnosis of membranous nephropathy. Because of both the difference in treatment responses and the treatment-related side effects, membranous nephropathy treatment should be individualized. In addition, it is recommended to make a treatment plan by calculating the risk of progressive kidney fail-ure of the disease. Parallel to the changes in diagnosis and follow-up, treatment plans in membranous nephropathy have undergone severe changes in recent years. As the autoimmunity targets in the pathogenesis of the disease become clearer, treatment has turned to more specific therapies that are more selective in targeting antibody-producing cells, such as rituximab. This article described the new developments in the pathogenesis, diagnosis, and treatment of membranous nephropathy.
dc.description.sponsorshipScientific Research Fund of the Karadeniz Technical University [THD-2018-7309]
dc.description.sponsorshipFunding study was financed by the Scientific Research Fund of the Karadeniz Technical University (THD-2018-7309) .
dc.identifier.doi10.5152/turkjnephrol.2023.22123421
dc.identifier.issn2667-4440
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85154052131
dc.identifier.scopusqualityQ4
dc.identifier.trdizinid1165014
dc.identifier.urihttps://doi.org/10.5152/turkjnephrol.2023.22123421
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1165014
dc.identifier.urihttps://hdl.handle.net/11480/15702
dc.identifier.volume32
dc.identifier.wosWOS:000977236600002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectAnti-phospholipase A2 antibody
dc.subjectmembranous nephropathy
dc.subjectnephrotic syndrome
dc.subjectrituximab
dc.titleMembranous Nephropathy: Current Understanding in The Light of New Advances
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu